---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-057711"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T17:30:57.505089+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics Q1 net loss $9.2M; cash runway through Q2 2025; SHINE data mid-2024

## Summary
- Net loss of $9.2M ($0.27/share) vs $6.2M ($0.21/share) in Q1 2023.
- Cash and equivalents $34.7M plus $62.3M in NIA grant funds; sufficient through Q2 2025.
- R&D expenses rose to $10.6M from $5.4M, driven by Phase 2 trial activities.
- Topline SHINE (Alzheimer's) results expected mid-2024; SHIMMER (DLB) enrolled 130 participants.
- Completed follow-on offering in March 2024, netting $11.9M.

## SEC filing metadata
- accession: 0001104659-24-057711
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465924057711/0001104659-24-057711-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465924057711/tm2413335d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-057711
- JSON: https://secwatch.observer/filing/0001104659-24-057711.json
- Plain text: https://secwatch.observer/filing/0001104659-24-057711.txt

## Key facts
- Earnings Releases
  COGNITION THERAPEUTICS INC reported first quarter ended March 31, 2024 results: net income $9.2 million, EPS $(0.27) per basic and diluted share.
  - Period: first quarter ended March 31, 2024
  - Net income: $9.2 million
  - EPS: $(0.27) per basic and diluted share
  - Result: reported results
  source text: The Company reported a net loss of $9.2 million, or $(0.27) per basic and diluted share for the first quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1455365/000110465924057711/0001104659-24-057711-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.